+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Uveitis Treatment Market by Drug Class, Disease Type and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • PDF Icon

    Report

  • 261 Pages
  • February 2020
  • Region: Global
  • Allied Market Research
  • ID: 5019888
Description Jump to:
The global uveitis treatment market was valued at $478 million in 2018, and is projected to reach $687 million by 2026, registering a CAGR of 4.6% from 2019 to 2026.


Uveitis is the inflammation of the middle layer of tissue in the eye wall uvea that consists of the iris, choroid, and ciliary body. Different forms of drug such as cycloplegic agents, anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others are used in the treatment of uveitis. Different types of uveitis include anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis. The most common type of uveitis is an inflammation of iris called iritis or anterior uveitis. Uveitis can be serious, leading to permanent vision loss.

The uveitis treatment market is expected to experience significant growth during the forecast period, owing to increase in prevalence of uveitis, rise in popularity of advanced therapeutics, and wide availability of drugs. In addition, early detection of the disease and surge in R&D activities to developed ideal therapeutics further fuel the market growth. However, unknown etiology and pathophysiology of uveitis and adverse effects associated with the treatment therapeutics may hamper the market growth.

The global uveitis treatment market is segmented on the basis of drug class, distribution channel, and region. Based on drug class, the market is classified into anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others. Disease type such as anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis are covered in the report. According to distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Based on region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Drug Class
  • Anti-inflammatory
  • Antimicrobial Drugs
  • Immunotherapy & Targeted Therapies
  • Others

Disease Type

  • Anterior Uveitis
  • Posterior Uveitis
  • Intermediate Uveitis
  • Panuveitis

By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Providers

By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • AbbVie Inc.
  • Alimera Sciences, Inc.
  • Allergan Plc.
  • Amgen Inc.
  • Bausch Health Companies Inc. (Bausch & Lomb Incorporated)
  • Clearside Biomedical, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • Mylan N.V.
  • Novartis AG
  • Santen Pharmaceutical Co., Ltd.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • Aldeyra Therapeutics, Inc.
  • Aciont Inc.

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. Key findings
2.2.1. Top investment pockets
2.2.2. Market player positioning, 2018
2.3. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key forces shaping uveitis treatment industry/market
3.2.1. Moderate power of suppliers
3.2.2. High threat of new entrants
3.2.3. High threat of substitution
3.2.4. Moderate competitive rivalry
3.2.5. Moderate bargaining power of buyers
3.3. Market dynamics
3.3.1. Drivers
3.3.1.1. Increase in prevalence of uveitis
3.3.1.2. Potential drugs in pipeline
3.3.1.3. Surge in healthcare expenditure worldwide
3.3.2. Restraint
3.3.2.1. Unknown etiology of uveitis
3.3.3. Opportunities
3.3.3.1. Growth opportunities in emerging markets
3.3.3.2. Higher number of unmet needs for treatment of uveitis
3.3.4. Impact analysis
CHAPTER 4: UVEITIS TREATMENT MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Anti-inflammatory
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Antimicrobial drugs
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Immunotherapy & targeted therapies
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Others
4.5.1. Key market trends and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
CHAPTER 5: UVEITIS TREATMENT MARKET, BY DISEASE TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Anterior uveitis
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Posterior uveitis
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Intermediate uveitis
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Panuveitis
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
CHAPTER 6: UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals pharmacies
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Drug stores and retail pharmacies
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Online pharmacies
6.4.1. Market size and forecast
6.4.2. Market analysis, by country
CHAPTER 7: UVEITIS TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. uveitis treatment market, by drug class
7.2.2.1.2. U.S. uveitis treatment market, by disease type
7.2.2.1.3. U.S. uveitis treatment market, by distribution channel
7.2.2.2. Canada
7.2.2.2.1. Canada uveitis treatment market, by drug class
7.2.2.2.2. Canada uveitis treatment market, by disease type
7.2.2.2.3. Canada uveitis treatment market, by distribution channel
7.2.2.3. Mexico
7.2.2.3.1. Mexico uveitis treatment market, by drug class
7.2.2.3.2. Mexico uveitis treatment market, by disease type
7.2.2.3.3. Mexico uveitis treatment market, by distribution channel
7.2.3. North America market size and forecast, by drug class
7.2.4. North America uveitis treatment market, by disease type
7.2.5. North America uveitis treatment market, by distribution channel
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany uveitis treatment market, by drug class
7.3.2.1.2. Germany uveitis treatment market, by disease type
7.3.2.1.3. Germany uveitis treatment market, by distribution channel
7.3.2.2. France
7.3.2.2.1. France uveitis treatment market, by drug class
7.3.2.2.2. France uveitis treatment market, by disease type
7.3.2.2.3. France uveitis treatment market, by distribution channel
7.3.2.3. UK
7.3.2.3.1. UK uveitis treatment market, by drug class
7.3.2.3.2. UK uveitis treatment market, by disease type
7.3.2.3.3. UK uveitis treatment market, by distribution channel
7.3.2.5. Italy
7.3.2.5.1. Italy uveitis treatment market, by drug class
7.3.2.5.2. Italy uveitis treatment market, by disease type
7.3.2.5.3. Italy uveitis treatment market, by distribution channel
7.3.2.6. Spain
7.3.2.6.1. Spain uveitis treatment market, by drug class
7.3.2.6.2. Spain uveitis treatment market, by disease type
7.3.2.6.3. Spain uveitis treatment market, by distribution channel
7.3.2.7. Rest of Europe
7.3.2.7.1. Rest of Europe uveitis treatment market, by drug class
7.3.2.7.2. Rest of Europe uveitis treatment market, by disease type
7.3.2.7.3. Rest of Europe uveitis treatment market, by distribution channel
7.3.3. Europe market size and forecast, by drug class
7.3.4. Europe uveitis treatment market, by disease type
7.3.5. Europe uveitis treatment market, by distribution channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan
7.4.2.1.1. Japan uveitis treatment market, by drug class
7.4.2.1.2. Japan uveitis treatment market, by disease type
7.4.2.1.3. Japan uveitis treatment market, by distribution channel
7.4.2.2. China
7.4.2.2.1. China uveitis treatment market, by drug class
7.4.2.2.2. China uveitis treatment market, by disease type
7.4.2.2.3. China uveitis treatment market, by distribution channel
7.4.2.3. Australia
7.4.2.3.1. Australia uveitis treatment market, by drug class
7.4.2.3.2. Australia uveitis treatment market, by disease type
7.4.2.3.3. Australia uveitis treatment market, by distribution channel
7.4.2.5. India
7.4.2.5.1. India uveitis treatment market, by drug class
7.4.2.5.2. India uveitis treatment market, by disease type
7.4.2.5.3. India uveitis treatment market, by distribution channel
7.4.2.6. South Korea
7.4.2.6.1. South Korea uveitis treatment market, by drug class
7.4.2.6.2. South Korea uveitis treatment market, by disease type
7.4.2.6.3. South Korea uveitis treatment market, by distribution channel
7.4.2.7. Rest of Asia-Pacific
7.4.2.7.1. Rest of Asia-Pacific uveitis treatment market, by drug class
7.4.2.7.2. Rest of Asia-Pacific uveitis treatment market, by disease type
7.4.2.7.3. Rest of Asia-Pacific uveitis treatment market, by distribution channel
7.4.3. Asia-Pacific market size and forecast, by drug class
7.4.4. Asia-Pacific uveitis treatment market, by disease type
7.4.5. Asia-Pacific uveitis treatment market, by distribution channel
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil
7.5.2.1.1. Brazil uveitis treatment market, by drug class
7.5.2.1.2. Brazil uveitis treatment market, by disease type
7.5.2.1.3. Brazil uveitis treatment market, by distribution channel
7.5.2.3. Saudi Arabia
7.5.2.3.1. Saudi Arabia uveitis treatment market, by drug class
7.5.2.3.2. Saudi Arabia uveitis treatment market, by disease type
7.5.2.3.3. Saudi Arabia uveitis treatment market, by distribution channel
7.5.2.4. South Africa
7.5.2.4.1. South Africa uveitis treatment market, by drug class
7.5.2.4.2. South Africa uveitis treatment market, by disease type
7.5.2.4.3. South Africa uveitis treatment market, by distribution channel
7.5.2.5. Rest of LAMEA
7.5.2.5.1. Rest of LAMEA uveitis treatment market, by drug class
7.5.2.5.2. Rest of LAMEA uveitis treatment market, by disease type
7.5.2.5.3. Rest of LAMEA uveitis treatment market, by distribution channel
7.5.3. LAMEA market size and forecast, by drug class
7.5.4. LAMEA uveitis treatment market, by disease type
7.5.5. LAMEA uveitis treatment market, by distribution channel
CHAPTER 8: COMPANY PROFILES
8.1. AbbVie Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. Alimera Sciences, Inc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Allergan Plc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. Amgen Inc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3.
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Bausch Health Companies Inc. (Bausch & Lomb Incorporated)
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. Clearside Biomedical, Inc.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Product Portfolio
8.6.4. Business performance
8.7. EyePoint Pharmaceuticals, Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Product Portfolio
8.7.4. Key strategic moves and developments
8.8. Mylan N.V.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. Novartis AG
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. Santen Pharmaceutical Co., Ltd.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Product portfolio
8.10.4. Business performance

Executive Summary

According to the report titled 'Uveitis Treatment Market by Drug Class, Disease Type, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the global uveitis treatment market size was valued at $478 million in 2018, and is projected to reach $687million by 2026, growing at a CAGR of 4.6% from 2019 to 2026.

Uveitis is characterized by inflammation of the middle layer of the eye, which is called the uvea. It may occur from both infectious and non-infectious causes. Different types of medication such as cycloplegic agents, anti-inflammatory, and immunotherapy & targeted therapies, antimicrobial drugs, and others are used in the treatment of uveitis.

The uveitis treatment market is expected to experience significant growth during the forecast period, owing to rise in demand for uveitis treatment medication across geographies with increase in popularity advanced therapeutics. Furthermore, increase in prevalence of uveitis with early detection further boost the uveitis treatment market growth during the forecast period. However, lack of adverse effects associated with the use of drugs may hamper the market growth. Moreover, significant unmet need for uveitis treatment and innovative molecules in pipeline further create lucrative opportunities for uveitis treatment market.

Based on drug class, the uveitis market is categorized into anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others. Currently, anti-inflammatory is major revenue contributing segment and is estimated to witness significant market growth during the forecast period due to adoption of anti-inflammatory as first line treatment of uveitis. On the other hand, immunotherapy & targeted therapies segment is expected to witness fastest market growth due to rise in demand for ideal therapeutics for treatment of uveitis.

According to distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. The online providers segment is anticipated to depict significant growth during the forecast period due to rise in preference for online purchasing of drugs over the traditional methods, increase in awareness of online pharmacy, and rise in number of internet users.

According to Onkar Sumant, Manager, Healthcare, “The growth of the uveitis market is attributed to rise in prevalence of uveitis disorders across the globe. Furthermore, growth in treatment awareness and rise in adoption of uveitis treatments contribute to the growth of the market.”

KEY FINDINGS OF THE STUDY
  • Based on drug class, the anti-inflammatory segment held approximately half of the share in the global market in 2018.
  • Based on distribution channel, the online pharmacies segment exhibits fastest growth and is expected to grow at a CAGR of 5.9% from 2019 to 2026.
  • Based on application, the anterior uveitis segment held largest market share in 2018 and is expected to remain dominant throughout the forecast period.
  • Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 6.0% during the forecast period.

North America accounted for approximately one-half of the global uveitis treatment market share in 2018 and is expected to remain dominant throughout the forecast period. This was attributed to the higher adoption of ideal uveitis treatment medication, higher number of R&D activities to develop ideal therapeutics, large number of target population with higher health awareness, availability of trained medical professionals, and supportive reimbursement policies in the healthcare system. Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to growth in prevalence of uveitis with increase in adoption of uveitis treatment medication.

Companies Mentioned

  • AbbVie Inc.
  • Alimera Sciences Inc.
  • Allergan Plc.
  • Amgen Inc.
  • Bausch Health Companies Inc.(Bausch & Lomb Incorporated)
  • Clearside Biomedical Inc.
  • EyePoint Pharmaceuticals Inc.
  • Mylan N.V.
  • Novartis AG
  • Santen Pharmaceutical Co. Ltd.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages261
PublishedFebruary 2020
Forecast Period2018 - 2026
Estimated Market Value ( USD ) in 2018 $ 478 million
Forecasted Market Value ( USD ) by 2026 $ 687 million
Compound Annual Growth Rate4.6%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Uveitis Drugs Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F - Product Image

Uveitis Drugs Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F

  • Report
  • 190 Pages
  • Global
From
Uveitis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Uveitis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 147 Pages
  • Global
Global Uveitis Drugs Market by Treatment Type (Analgesics, Antibiotics, Antifungal), Disease Type (Anterior Uveitis, Intermediate Uveitis, Panuveitis), Cause, Distribution Channel - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Forecast 2023-2030 - Product Image

Global Uveitis Drugs Market by Treatment Type (Analgesics, Antibiotics, Antifungal), Disease Type (Anterior Uveitis, Intermediate Uveitis, Panuveitis), Cause, Distribution Channel - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Forecast 2023-2030

  • Report
  • 183 Pages
  • Global
From
Global Uveitis Treatment Market by Treatment Type (Analgesics, Antibiotics, Antifungal), Disease Type (Anterior Uveitis, Intermediate Uveitis, Panuveitis), Cause, Distribution Channel - Forecast 2024-2030 - Product Image

Global Uveitis Treatment Market by Treatment Type (Analgesics, Antibiotics, Antifungal), Disease Type (Anterior Uveitis, Intermediate Uveitis, Panuveitis), Cause, Distribution Channel - Forecast 2024-2030

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.